vs

Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and ESPEY MFG & ELECTRONICS CORP (ESP). Click either name above to swap in a different company.

ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $12.1M, roughly 1.5× ESPEY MFG & ELECTRONICS CORP). ESPEY MFG & ELECTRONICS CORP runs the higher net margin — 23.1% vs -64.1%, a 87.2% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs -10.8%). ESPEY MFG & ELECTRONICS CORP produced more free cash flow last quarter ($-4.1M vs $-11.8M). Over the past eight quarters, ESPEY MFG & ELECTRONICS CORP's revenue compounded faster (21.3% CAGR vs 4.5%).

Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.

ESPEY MFG & ELECTRONICS CORP is a US-based manufacturer specializing in high-reliability power supplies, power conversion systems and specialized electronic components. It serves aerospace, defense, industrial and transportation sectors, delivering custom solutions for harsh environments to OEMs and government contractors across North America and select global markets.

ENTA vs ESP — Head-to-Head

Bigger by revenue
ENTA
ENTA
1.5× larger
ENTA
$18.6M
$12.1M
ESP
Growing faster (revenue YoY)
ENTA
ENTA
+20.6% gap
ENTA
9.8%
-10.8%
ESP
Higher net margin
ESP
ESP
87.2% more per $
ESP
23.1%
-64.1%
ENTA
More free cash flow
ESP
ESP
$7.7M more FCF
ESP
$-4.1M
$-11.8M
ENTA
Faster 2-yr revenue CAGR
ESP
ESP
Annualised
ESP
21.3%
4.5%
ENTA

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
ENTA
ENTA
ESP
ESP
Revenue
$18.6M
$12.1M
Net Profit
$-11.9M
$2.8M
Gross Margin
34.7%
Operating Margin
-60.5%
25.3%
Net Margin
-64.1%
23.1%
Revenue YoY
9.8%
-10.8%
Net Profit YoY
46.4%
47.0%
EPS (diluted)
$-0.42
$0.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENTA
ENTA
ESP
ESP
Q4 25
$18.6M
$12.1M
Q3 25
$15.1M
$9.1M
Q2 25
$18.3M
$9.6M
Q1 25
$14.9M
$10.3M
Q4 24
$17.0M
$13.6M
Q3 24
$14.6M
$10.4M
Q2 24
$18.0M
$11.6M
Q1 24
$17.1M
$8.3M
Net Profit
ENTA
ENTA
ESP
ESP
Q4 25
$-11.9M
$2.8M
Q3 25
$-18.7M
$2.2M
Q2 25
$-18.3M
$2.9M
Q1 25
$-22.6M
$1.7M
Q4 24
$-22.3M
$1.9M
Q3 24
$-28.8M
$1.6M
Q2 24
$-22.7M
$1.9M
Q1 24
$-31.2M
$1.0M
Gross Margin
ENTA
ENTA
ESP
ESP
Q4 25
34.7%
Q3 25
35.4%
Q2 25
39.3%
Q1 25
28.6%
Q4 24
23.2%
Q3 24
26.8%
Q2 24
27.6%
Q1 24
25.0%
Operating Margin
ENTA
ENTA
ESP
ESP
Q4 25
-60.5%
25.3%
Q3 25
-121.6%
22.7%
Q2 25
-103.2%
27.4%
Q1 25
-164.3%
17.0%
Q4 24
-138.8%
14.9%
Q3 24
-204.4%
16.5%
Q2 24
-134.6%
18.4%
Q1 24
-192.1%
13.2%
Net Margin
ENTA
ENTA
ESP
ESP
Q4 25
-64.1%
23.1%
Q3 25
-123.6%
23.9%
Q2 25
-99.7%
30.6%
Q1 25
-151.7%
16.5%
Q4 24
-131.4%
14.0%
Q3 24
-197.3%
15.3%
Q2 24
-126.1%
16.3%
Q1 24
-182.7%
12.5%
EPS (diluted)
ENTA
ENTA
ESP
ESP
Q4 25
$-0.42
$0.99
Q3 25
$-0.88
$0.76
Q2 25
$-0.85
$1.07
Q1 25
$-1.06
$0.63
Q4 24
$-1.05
$0.71
Q3 24
$-1.36
$0.61
Q2 24
$-1.07
$0.73
Q1 24
$-1.47
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENTA
ENTA
ESP
ESP
Cash + ST InvestmentsLiquidity on hand
$37.4M
$17.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$126.6M
$53.2M
Total Assets
$329.5M
$85.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENTA
ENTA
ESP
ESP
Q4 25
$37.4M
$17.8M
Q3 25
$32.3M
$22.2M
Q2 25
$44.8M
$18.9M
Q1 25
$60.2M
$13.9M
Q4 24
$84.3M
$8.0M
Q3 24
$37.2M
$4.8M
Q2 24
$35.8M
$4.4M
Q1 24
$63.5M
$5.6M
Stockholders' Equity
ENTA
ENTA
ESP
ESP
Q4 25
$126.6M
$53.2M
Q3 25
$64.7M
$51.0M
Q2 25
$79.3M
$50.8M
Q1 25
$93.5M
$46.3M
Q4 24
$111.8M
$44.8M
Q3 24
$128.8M
$42.5M
Q2 24
$148.9M
$41.3M
Q1 24
$166.1M
$39.3M
Total Assets
ENTA
ENTA
ESP
ESP
Q4 25
$329.5M
$85.2M
Q3 25
$280.7M
$84.8M
Q2 25
$301.0M
$79.1M
Q1 25
$323.0M
$72.8M
Q4 24
$348.6M
$60.2M
Q3 24
$376.7M
$57.6M
Q2 24
$398.8M
$56.5M
Q1 24
$413.6M
$53.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENTA
ENTA
ESP
ESP
Operating Cash FlowLast quarter
$-11.7M
$-2.8M
Free Cash FlowOCF − Capex
$-11.8M
$-4.1M
FCF MarginFCF / Revenue
-63.6%
-34.1%
Capex IntensityCapex / Revenue
0.8%
10.9%
Cash ConversionOCF / Net Profit
-1.00×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M
$11.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENTA
ENTA
ESP
ESP
Q4 25
$-11.7M
$-2.8M
Q3 25
$-6.5M
$5.7M
Q2 25
$17.5M
$2.8M
Q1 25
$-13.5M
$11.5M
Q4 24
$-16.8M
$5.4M
Q3 24
$-10.4M
$1.4M
Q2 24
$-14.8M
$3.2M
Q1 24
$-28.6M
$1.4M
Free Cash Flow
ENTA
ENTA
ESP
ESP
Q4 25
$-11.8M
$-4.1M
Q3 25
$-7.9M
$4.4M
Q2 25
$17.4M
$915.3K
Q1 25
$-16.0M
$10.5M
Q4 24
$-25.5M
$4.5M
Q3 24
$-19.4M
$724.8K
Q2 24
$-21.3M
$2.6M
Q1 24
$-30.3M
$379.1K
FCF Margin
ENTA
ENTA
ESP
ESP
Q4 25
-63.6%
-34.1%
Q3 25
-52.5%
48.7%
Q2 25
94.7%
9.5%
Q1 25
-107.4%
101.8%
Q4 24
-150.6%
33.0%
Q3 24
-132.5%
6.9%
Q2 24
-118.6%
22.2%
Q1 24
-177.5%
4.6%
Capex Intensity
ENTA
ENTA
ESP
ESP
Q4 25
0.8%
10.9%
Q3 25
9.6%
14.2%
Q2 25
0.8%
19.3%
Q1 25
17.0%
9.3%
Q4 24
51.6%
6.5%
Q3 24
61.3%
6.4%
Q2 24
36.4%
5.7%
Q1 24
9.8%
12.5%
Cash Conversion
ENTA
ENTA
ESP
ESP
Q4 25
-1.00×
Q3 25
2.64×
Q2 25
0.95×
Q1 25
6.72×
Q4 24
2.82×
Q3 24
0.87×
Q2 24
1.71×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ENTA
ENTA

Segment breakdown not available.

ESP
ESP

ASC606$11.3M93%
Other$855.0K7%

Related Comparisons